Skip to main content Back to Top
Advertisement

8/19/2019

Cefuroxime Sodium Injection

Products Affected - Description

    • Cefuroxime powder for solution for injection, Sagent, 1.5 gram, vial, 25 count, NDC 25021-0119-20
    • Cefuroxime powder for solution for injection, Sagent, 750 mg, vial, 25 count, NDC 25021-0118-10

Reason for the Shortage

    • Sagent had cefuroxime injection on shortage due to manufacturing delays and increased demand.
    • Teligent discontinued all Zinacef presentations in February 2018.
    • Hikma did not provide a reason for the cefuroxime injection shortage. They are not currently marketing the 7.5 gram vials.

Available Products

    • Cefuroxime powder for solution for injection, Hikma, 1.5 gram, vial, 25 count, NDC 00143-9977-22
    • Cefuroxime powder for solution for injection, Hikma, 750 mg, vial, 25 count, NDC 00143-9979-22

Estimated Resupply Dates

    • Sagent has cefuroxime 750 mg and 1.5 gram vials on allocation.

Updated

Updated August 19, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 25, 2013 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins